Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma

This study tests whether giving patients with newly diagnosed multiple myeloma their own immune cells (called NK cells) — either alone or combined with an antibody drug called isatuximab — after standard intensive chemotherapy can help maintain remission longer. **You may be eligible if...** - You are 18 or older with active multiple myeloma - Your myeloma shows measurable disease markers in blood or urine tests - You are newly diagnosed and being considered for high-dose chemotherapy - You are in good general health (ECOG performance status 0 or 1) **You may NOT be eligible if...** - You are pregnant or breastfeeding - You are not using adequate contraception (if applicable) - You have significant organ dysfunction unrelated to myeloma Talk to your doctor to see if this trial is right for you.